October 18, 2012 - LifeVest, AutoPulse, and Temperature Management Solutions to be Showcased at TCT 2012


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
[email protected]  



October 18, 2012—CHELMSFORD, MASS.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator, the AutoPulse® Non-invasive Cardiac Support Pump, and ZOLL’s Intravascular Temperature Management (IVTM™) solution in Booth 873 at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting October 22-26 at the Miami Beach Convention Center.

One out of every five acute myocardial infarction (AMI) patients is at high-risk of dying following a percutaneous coronary intervention (PCI) procedure.1 The majority of mortality in AMI patients post-PCI occurs in the first three months—one out of every 10 high risk patients die, with about 60% of this mortality due to sudden cardiac death.2 Data has demonstrated that protecting patients with the LifeVest post-PCI is associated with an 80% reduction in total mortality at 90 days and a 57% reduction over as much as three years compared to a matched cohort of patients not prescribed the LifeVest.3

“The LifeVest has been proven to significantly reduce total mortality in patients in the first 90 days following a coronary intervention,” said Richard A. Packer, Chief Executive Officer of ZOLL. “LifeVest is commonly worn by patients for 90 days following revascularization. The fact that the mortality benefit of the LifeVest extends well beyond the time patients typically wear the device is remarkable in that it may indicate potential clinical benefits related to optimization of medical therapy and patient compliance with prescribed treatment and follow-up, along with other broad healthcare impacts.”

The LifeVest is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.

The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.

ZOLL’s AutoPulse is an automated, portable chest compression device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during SCA. The AutoPulse delivers high-quality, uninterrupted CPR chest compressions to maintain myocardial and cerebral perfusion even when moving patients, traveling in an ambulance or while a patient is undergoing PCI. Additionally, it offers the benefit of freeing up clinicians to focus on other life-saving interventions.

ZOLL’s Intravascular Temperature Management (IVTM) solution offers health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP® delivers accurate, easy-to-use and cost-effective control for both cooling and warming applications.

For more information, go to www.zoll.com or call 1-800-804-4356.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. For more information, visit www.zoll.com.

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

Copyright © 2012 ZOLL Medical Corporation. All rights reserved. AutoPulse, IVTM, LifeVest, ThermoGuard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation All product names are the property of their respective owners.

1Halkin, A, et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. Journal of the American College of Cardiology, 2005; 45: 1397-1405.
2Stone, G, et al. “Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients.” April 2011. Available at http://www.theheart.org/article/1202823.do.
3Zishiri et al, “Use of the Wearable Cardioverter Defibrillator and Survival After Coronary Artery Revascularization in Patients with Left Ventricular Dysfunction [Abstract],” Circulation, 2011, 124:A9816.